NDAORALTABLET, ORALLY DISINTEGRATINGPriority Review
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
5/8 — Partial
Priority Review
NURTEC ODT (rimegepant sulfate) by Pfizer is gene-related peptide receptor antagonist. First approved in 2020.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NURTEC ODT is an orally disintegrating tablet containing rimegepant sulfate, a small-molecule CGRP receptor antagonist developed by Pfizer. It is indicated for the acute treatment of migraine in adults. The drug works by blocking calcitonin gene-related peptide signaling, a key pathway in migraine pathophysiology.
$0.478BPart D
PeakStable
12.8 years to LOEStrong peak-cycle commercial activity with 329K annual Part D claims indicates mature market penetration and substantial commercial infrastructure supporting field and marketing teams.
Mechanism of Action
gene-related peptide receptor antagonist.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (12)
A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea
Started Oct 2026
3,000 enrolled
Migraine With or Without Aura
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
Started May 2026
400 enrolled
Acute Treatment of Migraine
Consistency of Response With Rimegepant in Acute Treatment of Migraine
Started Nov 2025
250 enrolled
Migraine
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
Started Sep 2025
60 enrolled
MigraineTrigger Induced Migraine
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
Started Oct 2024
1,395 enrolled
Migraine
Worked on NURTEC ODT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.